Method of treating graft versus host disease

Abstract

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.

1 . A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the patient a population of cells enriched for STRO-1 bright  cells and/or progeny thereof. 
     
     
         2 . The method according to  claim 1  which comprises administering to the patient (a) precursors of bone marrow lineage cells, and (b) a population of cells enriched for STRO-1 bright  cells and/or progeny thereof. 
     
     
         3 . The method according to  claim 2 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered to the patient prior to administration of the precursors of bone marrow lineage cells. 
     
     
         4 . The method according to  claim 2 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is co-administered with the precursors of bone marrow lineage cells. 
     
     
         5 . The method according to  claim 2 , wherein the precursors of bone marrow lineage cells are allogeneic cells administered to the patient to treat a malignant or genetic disease of the blood. 
     
     
         6 . The method according to  claim 1 , wherein the STRO-1 bright  cells and/or progeny thereof are allogeneic. 
     
     
         7 . The method according to  claim 1 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered systemically. 
     
     
         8 . The method according to  claim 7 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered intravenously. 
     
     
         9 . The method of  claim 1 , comprising administering between 0.1×10 6  and 5×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         10 . The method of  claim 1 , comprising administering between 0.3×10 6  and 2×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         11 . The method of  claim 1 , comprising administering a low dose of STRO-1 bright  cells and/or progeny thereof. 
     
     
         12 . The method of  claim 11 , wherein the low dose of STRO-1 bright  cells and/or progeny thereof comprises between 0.1×10 5  and 0.5×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         13 . The method of  claim 11 , wherein the low dose of STRO-1 bright  cells and/or progeny thereof comprises about 0.3×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         14 . The method of  claim 1 , wherein the population enriched for STRO-1 bright  cells and/or progeny thereof are administered once weekly or less often. 
     
     
         15 . The method according to  claim 1 , wherein the patient is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy. 
     
     
         16 . The method according to  claim 1 , further comprising administering an immunosuppressive drug to the patient.